TG Therapeutics recently initiated an open-label Phase 2 trial of BRIUMVI (ublituximab-xiiy) in about 60 adults with ...
The collaboration will bring Cortechs.ai's quantitative MRI analysis into Viz.ai's care coordination platform, beginning with ...
Earlier MS diagnosis is now possible, Zyn nicotine pouches get an FDA risk claim, and norovirus concerns rise with summer ...
A new study uses generative AI and MMCLE to reveal invisible gray matter cortical lesions on legacy MS MRI scans.
The partnership brings quantitative MRI into real-time clinical workflows, helping neurologists track disease progression and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results